---
schema_version: "secwatch.filing_event.v1"
accession: "0002070849-26-000029"
form_type: "8-K"
ticker: "BLLN"
cik: "0002070849"
company_name: "BillionToOne, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:58:51.347711+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BillionToOne Q1 revenue $108.4M (+84% YoY), raises FY 2026 guidance to $450M-$465M

## Summary
- Net income $18.0M ($0.34 diluted) vs loss of $4.0M (-$0.39) in Q1 2025.
- Gross margin improved to 73% from 64% YoY; operating income $17.8M vs loss $2.3M.
- Oncology revenue surged 392% to $10.7M; prenatal revenue up 72% to $96.5M.
- Full-year 2026 revenue guidance raised to $450M-$465M from prior $430M-$445M.
- Launched Unity Confirm non-invasive confirmation assay for high-risk prenatal results.

## SEC filing metadata
- accession: 0002070849-26-000029
- form_type: 8-K
- ticker: BLLN
- cik: 0002070849
- company_name: BillionToOne, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2070849/000207084926000029/0002070849-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2070849/000207084926000029/blln-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002070849-26-000029
- JSON: https://secwatch.observer/filing/0002070849-26-000029.json
- Plain text: https://secwatch.observer/filing/0002070849-26-000029.txt

## Source-grounded claims
- claim_id: 09040b27aa3b1fc47190efa20e11d4fd7a4d266b
  claim: BillionToOne, Inc. reported first quarter ended March 31, 2026 results: revenue $108.4 million, net income $18.0 million, or $0.34 per diluted share, EPS $0.34 per diluted share. Guidance raised.
  evidence_excerpt: to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026. Financial Highlights: ● Total revenue of $108.4 million in the first quarter of 2026, compared to $59.0 million in the first quarter of 2025, an increase of 84%. ● Prenatal clinical testing revenue was $96.5 million in the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/2070849/000207084926000029/0002070849-26-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.